Catalyst

Slingshot members are tracking this event:

There were 13 deaths across Phase 2b clinical trial assessing voclosporin in patients with active lupus nephritis (LN): (2) in the high-dose voclosporin arm; (10) in the low-dose voclosporin arm (10); and (1) in the control arm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AUPH

50%

Additional Information

Additional Relevant Details
"The results of this trial are welcomed and exciting news for people with lupus and their doctors who are eager to have more tolerable and effective treatment options. Lupus-related kidney disease is one of the most serious and potentially life-threatening complications of lupus, affecting up to 60 percent of people with this autoimmune disease."This trial of voclosporin is the first trial of a potential treatment for active lupus nephritis to reach its primary endpoint, offering hope to individuals with lupus that an improved quality of life can soon be achieved. We are excited for the potential that the data from this study represents and we are eager to learn more details of additional analysis as they become available."We look forward to the timely commencement of a Phase III trial; and, should the findings confirm this study, the addition of this regimen to the arsenal of treatments available to people who have waited far too long for medicines that improve the quality of their lives."
http://www.marketwir...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 15, 2016
Related Keywords Voclosporin, Lupus Nephritis, Safety Data